论文部分内容阅读
目的:探究和分析米索前列醇预防产后出血的临床疗效。方法:选取我院2014年1月到2015年1月收治的94例单胎经引导分娩的产妇作为研究对象,随机分为实验组和对照组,其中实验组47例产妇,分娩后立即口服米索前列醇,对照组47例产妇,分娩后立即注射缩宫素,对比产后出血量以及不良反应。结果:实验组产妇产后2h出血量以及产后24h出血量均明显少于对照组。差异显著,有统计学意义(P<0.05)。实验组不良反应发生率为6.4%,对照组为8.5%,两组不良反应均较轻微,自行缓解,两组不良反应发生率差异不显著(P>0.05)。结论:米索前列醇有强烈的宫缩作用,可以有效预防产后出血,且效果优于缩宫素,不良反应较少,具有临床推广意义。
Objective: To investigate and analyze the clinical efficacy of misoprostol in preventing postpartum hemorrhage. Methods: A total of 94 single-fetus guided delivery women who were admitted to our hospital from January 2014 to January 2015 were randomly divided into experimental group and control group, in which 47 maternal women in the experimental group received oral administration immediately after delivery Supramostat and control group, 47 cases of mothers, oxytocin injection immediately after delivery, postpartum hemorrhage and adverse reactions. Results: The amount of bleeding at 2h postpartum and the amount of bleeding at 24h postpartum in experimental group were significantly less than those in control group. The difference was significant, with statistical significance (P <0.05). The incidence of adverse reactions was 6.4% in the experimental group and 8.5% in the control group. The adverse reactions in both groups were mild and relieved spontaneously. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Misoprostol has a strong contractile effect, which can effectively prevent postpartum hemorrhage, and the effect is better than oxytocin, with fewer adverse reactions, which has clinical significance.